BRIGHT MINDS BIOSCIENCES INC. (DRUG) Options Volume
1 BRIGHT MINDS BIOSCIENCES INC. (DRUG) option contracts changed hands in the latest session, at a put/call volume ratio of 0.00. This page tracks how actively DRUG options trade — contracts and dollars — and flags individual contracts running far above their own 30-day average volume.
Data as of Oct 12, 2026, 3:55 PM ET · OPRA data 15 minutes delayed · For information only — not investment advice.
Options Volume & Premium Flow
| Total options volume | 1 |
| Call volume | 1 |
| Put/call volume ratio | 0.00 |
| Listed contracts | 140 |
| Call premium traded | $352 |
| Premium put/call ratio | 0.00 |
| Open interest rank (31 day) | 100 / 100 |
DRUG Options Volume Trend
DRUG total options volume per session, past year.
DRUG put/call volume ratio, past year.
DRUG Unusual Options Activity
No DRUG contract currently trades at 3× its 30-day average volume with at least 500 contracts — nothing clears OptiView's unusual-activity bar today.
With a put/call volume ratio of 0.00, today's trading is tilted toward calls.
Explore the payoff profile of option on DRUG for free
Build multi-leg DRUG strategies, visualize payoffs, and scan the full US options universe with OptiView.
DRUG Options FAQ
How many DRUG options traded today?
1 DRUG option contracts traded as of Oct 12, 2026.
Is there unusual options activity in DRUG today?
No DRUG contract currently clears OptiView's unusual-activity bar as of Oct 12, 2026, which requires at least 3× the contract's 30-day average volume and 500 contracts traded.
Methodology. IV rank compares the current 30-day at-the-money implied volatility with its highest and lowest values over the past 52 weeks. Max pain is the strike that minimizes the total payout to option holders at expiration. The call and put walls are the strikes carrying the largest call and put open interest across all expirations. Net gamma exposure (GEX) is measured from the dealer perspective. All statistics are derived from delayed OPRA options data.
Options trading involves significant risk, and losses can exceed your initial investment. Always consult a licensed financial professional before making investment decisions. OptiView does not provide financial advice; all figures on this page are descriptive statistics, not recommendations.